The current study shows for the first time that diabetes does not promote aberrant cerebrovascularization in female rats. This contrasts with what we reported in male animals in various diabetes models. Deferoxamine preserved recognition memory function in diabetic female animals after stroke. The effect(s) of stroke and deferoxamine on cerebrovascular density and microglial activation also appear(s) to be different in female diabetic rats. Lastly, deferoxamine exerts detrimental effects on animals and BMVECs under control conditions.
Diabetes doubles the risk of vascular cognitive impairment, but the underlying reasons remain unclear. In the present study, we determined the temporal and spatial changes in the brain structure after microemboli (ME) injection using diffusion MRI (dMRI). Control and diabetic rats received cholesterol crystal ME (40–70 µm) injections. Cognitive tests were followed up to 16 weeks, while dMRI scans were performed at baseline and 12 weeks post-ME. The novel object recognition test had a lower d2 recognition index along with a decrease in spontaneous alternations in the Y maze test in diabetic rats with ME. dMRI showed that ME injection caused infarction in two diabetic animals (n=5) but none in controls (n=6). In diabetes, radial diffusivity (DR) was increased while fractional anisotropy (FA) was decreased in the cortex, indicating loss of tissue integrity and edema. In the dorsal hippocampus, mean diffusivity (MD), axial diffusivity (DA), and DR were significantly increased, indicating loss of axons and myelin damage. Histological analyses confirmed more tissue damage and microglial activation in diabetic rats with ME. These results suggest that ME injury and associated cerebrovascular dysfunction are greater in diabetes, which may cause cognitive deficits. Strategies to improve vascular function can be a preventive and therapeutic approach for vascular cognitive impairment.
Diabetes increases the risk of hemorrhagic transformation (HT) in ischemic stroke, especially with the use of tissue plasminogen activator (tPA). We showed that iron chelation therapy with deferoxamine (DFX) improves functional outcome in male diabetic animals after embolic stroke but its interaction with tPA remained unknown. We also reported that increased HT is associated with loss of cerebrovasculature in the recovery period in diabetic animals. This study tested the hypotheses that DFX treatment initiated after stroke 1) will improve neurological recovery after embolic stroke with tPA, and 2) will prevent cerebrovascular regression in diabetes. Control and type 2 diabetic animals were subjected to embolic middle cerebral artery occlusion. tPA (1 mg/kg) was given at 90 min post-occlusion. DFX (100 mg/kg) or vehicle was given every 12 h for 7 days after stroke. The composite score (Bederson’s score and beam walk), adhesive removal (ART) and novel object recognition (NOR) were assessed at day 3, 7 and 14 after the surgery. Cerebrovascularization indices in the ipsilateral cortex (vascular volume, surface area, and branch density) were measured with 3D imaging. DFX improved sensorimotor deficits in both groups and this effect was more robust in tPA combination. While DFX lowered vascularization indices in control animals, it prevented vasoregression in diabetes. Interestingly, DFX prevented the recovery of cognitive function in controls while improving it in diabetic animals. These results suggest that treatment with DFX may improve long term recovery in diabetes.